Overcoming obstacles to implementing methadone maintenance therapy for prisoners: Implications for policy and practice
DOI:
https://doi.org/10.5055/jom.2009.0024Keywords:
methadone, incarceration, prisoner health, opiate replacement therapyAbstract
More than 2.4 million people are currently incarcerated in the United States, many as a result of drugrelated offenses. In addition, more than 200,000 active heroin addicts pass through the correctional system annually. New evidence suggests that both providing prisoners with referrals for community-based methadone programs and providing methadone prior to release reduces recidivism and adverse health and social consequences associated with drug use. This article reports the programmatic challenges associated with initiating methadone treatment in the Rhode Island correctional system. Significant obstacles to implementing methadone treatment include: stigma associated with pharmacological treatment, misconceptions regarding the nature of opioid addiction, logistics of control and storage of methadone, increased work load for nursing staff, and general safety and control concerns. The authors discuss strategies to address these barriers and conclude that providing methadone prior to inmate release is a feasible intervention with the potential to mitigate drugrelated health and social harms.References
Glaze LE, Bonczar TP: Probation and Parole in the United States, 2007 Statistical Tables. Bureau of Justice Statistics 2008; Document NCJ 224707.
West HC, Sabol WJ: Prisoners in 2007. US Department of Justice 2008; Document NCJ 224280.
Blumstein A, Beck AJ: Population growth in US prisons, 1980-1996. In Tonry M, Petersilia J (eds.): Prisons, Crime and Justice: A Review of Research, Vol 26. Chicago: University of Chicago Press, 1999: 17-61.
Mauer M: The causes and consequences of prison growth in the United States. Punishment Soc. 2001; 3: 9-20.
Mumola CJ, Karberg JC: Drug Use and Dependence, State and Federal Prisons, 2004. US Department of Justice 2006; Document NCJ 213530.
Boutwell AE, Nijhawan A, Zaller N, et al.: Arrested on heroin: A national opportunity. J Opioid Manag. 2007; 3: 328-332.
Dole VP, Nyswander ME, Kreek MJ: Narcotic blockade. Arch Intern Med. 1966; 118: 304-309.
Connock M, Juarez-Garcia A, Jowett S, et al.: Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technol Assess. 2007; 11: 1-171, iii-iv.
Dolan KA, Shearer J, MacDonald M, et al.: A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003; 72: 59-65.
Gottheil E, Sterling RC, Weinstein SP: Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis. 1993; 12: 45-57.
Sees KL, Delucchi KL, Masson C, et al.: Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. JAMA. 2000; 283: 1303-1310.
McLellan AT, Arndt IO, Metzger DS, et al.: The effects of psychosocial services in substance abuse treatment. JAMA. 1993; 269: 1953-1959.
Caplehorn JR, Ross MW: Methadone maintenance and the likelihood of risky needle-sharing. Int J Addict. 1995; 30: 685-698.
Longshore D, Hsieh S, Danila B, et al.: Methadone maintenance and needle/syringe sharing. Int J Addict. 1993; 28: 983-996.
Metzger DS, Woody GE, McLellan AT, et al.: Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993; 6: 1049-1056.
Langendam MW, van Brussel GH, Coutinho RA, et al.: The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001; 91: 774-780.
Marsch LA: The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction. 1998; 93: 515-532.
Sheerin I, Green T, Sellman D, et al.: Reduction in crime by drug users on a methadone maintenance therapy programme in New Zealand. N Z Med J. 2004; 117: U795.
Anglin MD, McGlothlin WH, Speckart G: The effect of parole on methadone patient behavior. Am J Drug Alcohol Abuse. 1981; 8: 153-170.
McGlothlin WH, Anglin MD, Wilson BD: Outcome of the California Civil Addict commitments: 1961-1972. Drug Alcohol Depend. 1976; 1: 165-181.
Ward J, Mattick RP, Hall W: Methadone Maintenance Treatment and other Opioid Replacement Therapies. Australia: Harwood Academic Publishers, 1998.
Dole VP, Robinson JW, Orraca J, et al.: Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969; 280: 1372-1375.
Newman RG, Bashkow S, Cates M: Arrest histories before and after admission to a methadone maintenance treatment program. Proc Natl Conf Methadone Treat. 1973; 1: 109-115.
Tims FM, Leukefeld CG: Drug abuse treatment in prisons and jails. NIDA Research Monograph, Number 118. Washington, DC: US Government Printing Office, 1992.
Springer SA, Pesanti E, Hodges J, et al.: Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004; 38: 1754-1760.
Boutwell AE, Rich JD: Arrested, addicted: Heroin users in the Rhode Island Corrections System. Med Health R I. 2005; 88: 421-423.
Rapposelli KK, Kennedy MG, Miles JR, et al.: HIV/AIDS in correctional settings: a salient priority for the CDC and HRSA. AIDS Educ Prev. 2002; 14: 103-113.
Hammett TM, Gaiter JL, Crawford C: Reaching seriously atrisk populations: Health interventions in criminal justice settings. Health Educ Behav. 1998; 25: 99-120.
Nurco DN, Hanlon TE, Kinlock TW: Recent research on the relationship between illicit drug use and crime. Behav Sci Law. 1991; 9: 221-242.
Kinlock TW, Gordon MS, Schwartz RP, et al.: A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav. 2008; 35: 34-47.
Kinlock TW, Gordon MS, Schwartz RP, et al.: A randomized clinical trial of methadone maintenance for prisoners: Results at 1-month post-release. Drug Alcohol Depend. 2007; 91: 220-227.
Gordon MS, Kinlock TW, Schwartz RP, et al.: A randomized clinical trial of methadone maintenance for prisoners: Findings at 6 months post-release. Addiction. 2008; 103: 1333-1342.
Dolan KA, Shearer J, White B, et al.: Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction. 2005; 100: 820-828.
Springer SA, Bruce RD: A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. J Opioid Manag. 2008; 4: 81-86.
Rich JD, Boutwell AE, Shield DC, et al.: Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005; 82: 411-419.
Nunn A, Zaller N, Dickman S, et al.: Methadone and buprenorphine prescribing and referral practices in state and federal prisons: Results from a nationwide survey (Under Revision).
Rhode Island Department of Corrections: Population Report FY2008.
Zaller ND, Holmes L, Dyl AC, et al.: Linkage to treatment and supportive services among HIV-positive ex-offenders in Project Bridge. J Health Care Poor Underserved. 2008; 19: 522-531.
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
